Pacad Investment Ltd. bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to its most recent filing with the SEC. The institutional investor bought 9,650 shares of the company’s stock, valued at approximately $1,558,000.

A number of other institutional investors have also recently added to or reduced their stakes in IDXX. Bronfman E.L. Rothschild L.P. raised its position in IDEXX Laboratories by 2.3% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 770 shares of the company’s stock valued at $119,000 after buying an additional 17 shares in the last quarter. CAPROCK Group Inc. raised its position in IDEXX Laboratories by 2.2% in the second quarter. CAPROCK Group Inc. now owns 1,830 shares of the company’s stock valued at $295,000 after buying an additional 40 shares in the last quarter. Strs Ohio raised its position in IDEXX Laboratories by 0.7% in the second quarter. Strs Ohio now owns 5,929 shares of the company’s stock valued at $957,000 after buying an additional 41 shares in the last quarter. Fayez Sarofim & Co raised its position in IDEXX Laboratories by 1.4% in the first quarter. Fayez Sarofim & Co now owns 3,500 shares of the company’s stock valued at $541,000 after buying an additional 50 shares in the last quarter. Finally, HM Payson & Co. raised its position in IDEXX Laboratories by 0.4% in the first quarter. HM Payson & Co. now owns 21,091 shares of the company’s stock valued at $3,260,000 after buying an additional 85 shares in the last quarter. 87.69% of the stock is currently owned by hedge funds and other institutional investors.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at 155.43 on Friday. The company’s 50 day moving average is $157.88 and its 200 day moving average is $157.76. The company has a market capitalization of $13.57 billion, a price-to-earnings ratio of 53.47 and a beta of 0.49. IDEXX Laboratories, Inc. has a one year low of $102.45 and a one year high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.10. The company had revenue of $508.90 million for the quarter, compared to analysts’ expectations of $502.44 million. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. IDEXX Laboratories’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.74 earnings per share. Equities research analysts predict that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Pacad Investment Ltd. Buys Shares of 9,650 IDEXX Laboratories, Inc. (IDXX)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/01/pacad-investment-ltd-buys-shares-of-9650-idexx-laboratories-inc-idxx.html.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $187.00 price target on the stock in a report on Monday, May 29th. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a report on Tuesday, June 13th. Aegis assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, May 31st. They set a “sell” rating and a $118.00 price target on the stock. They noted that the move was a valuation call. BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Finally, CL King raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target on the stock in a report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. IDEXX Laboratories currently has a consensus rating of “Hold” and a consensus price target of $174.00.

In related news, Director Rebecca M. Henderson sold 2,578 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $152.86, for a total value of $394,073.08. Following the transaction, the director now directly owns 17,274 shares in the company, valued at $2,640,503.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Lawrence D. Kingsley acquired 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was bought at an average price of $151.76 per share, for a total transaction of $303,520.00. Following the completion of the transaction, the director now owns 3,344 shares of the company’s stock, valued at approximately $507,485.44. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 151,734 shares of company stock worth $23,436,626. 2.77% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.